Pdb17 - Real-World Dosing Behaviours and Outcomes When Switching to Ideglira From a Free Combination of Insulin and Glucagon-Like Peptide-1 Receptor Agonist Therapy
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.723
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV